N³-(4-(4-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-yl)piperazin-1-yl)phenyl)-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1H-1,2,4-triazole-3,5-diamine | 1037793-50-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N³-(4-(4-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-yl)piperazin-1-yl)phenyl)-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1H-1,2,4-triazole-3,5-diamine
• 英文别名: N³-(4-(4-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-yl)piperazin-1-yl)phenyl)-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-1-yl)-1H-1,2,4-triazole-3,5-diamine；N3-(4-(4-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-yl)piperazin-1-yl)phenyl)-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-1-yl)-1H-1,2,4-triazole-3,5-diamine；3-N-[4-[4-[(1S,2S,4R)-2-bicyclo[2.2.1]heptanyl]piperazin-1-yl]phenyl]-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine
• CAS: 1037793-50-2
• 化学式: C₂₆H₃₀ClN₉S
• 分子量: 536.104
• InChiKey: HLRDOMFIYHUBLJ-UWVAXJGDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  129
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  7-甲基-噻吩并[3,2-d]嘧啶-2,4(1h,3h)-二酮 在 肼 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 0.1h， 生成 N³-(4-(4-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-yl)piperazin-1-yl)phenyl)-1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-1H-1,2,4-triazole-3,5-diamine
  参考文献：
  名称：

  Discovery of dual Axl/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy

  摘要：

  Axl tyrosine kinase has been shown to be involved in multiple pathways contributing to tumor development, angiogenesis, and metastasis. High Axl expression has been observed in many human tumors where it appears to confer aggressive tumor behavior. Here we present several series of dual Axl-VEGF-R2 kinase inhibitors based on extensive optimization of an acyl diaminotriazole. It was hypothesized that dual inhibition of these two receptor tyrosine kinases may have a synergistic affect in inhibiting tumor angiogenesis and metastasis. One of these molecules, R916562 showed comparable activity to Sunitinib in two mouse tumor xenograft models and a mouse corneal micropocket model. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.06.071

文献信息

• SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS
  申请人：Goff Dane

  公开号：US20080188474A1

  公开（公告）日：2008-08-07

  Substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.

  本发明揭示了替代三唑和含有该化合物的制药组合物，其在抑制受体蛋白酪氨酸激酶Axl的活性方面是有用的。还揭示了使用该化合物治疗与Axl活性相关的疾病或病况的方法。
• Substituted triazoles useful as AXL inhibitors
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：EP2476679A2

  公开（公告）日：2012-07-18

  Substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.

  所公开的取代三唑类化合物和含有这些化合物的药物组合物有助于抑制受体蛋白酪氨酸激酶 Axl 的活性。还公开了使用这些化合物治疗与 Axl 活性相关的疾病或病症的方法。
• Substituted triazoles useful as Axl inhibitors
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US10166216B2

  公开（公告）日：2019-01-01

  Substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.

  所公开的取代三唑类化合物和含有这些化合物的药物组合物有助于抑制受体蛋白酪氨酸激酶 Axl 的活性。还公开了使用这些化合物治疗与 Axl 活性相关的疾病或病症的方法。
• WO2008/83356
  申请人：——

  公开号：——

  公开（公告）日：——
• US8906922B2
  申请人：——

  公开号：US8906922B2

  公开（公告）日：2014-12-09